Agila: the next billion dollar Indian acquisition in the works?
This article was originally published in Scrip
Agila Specialties is perhaps the next big deal on the horizon in the Indian pharmaceutical industry despite the carefully worded denial by Strides Arcolab's top brass on plans to hawk the firm’s crown jewel and injectables arm.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.